Arrhythmic Risk in Biventricular Pacing Compared With Left Bundle Branch Area Pacing: Results From the I-CLAS Study.

arrhythmias, cardiac atrial fibrillation cardiac pacing, artificial cardiac resynchronization therapy defibrillators, implantable tachycardia, ventricular

Journal

Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763

Informations de publication

Date de publication:
30 Jan 2024
Historique:
pubmed: 11 11 2023
medline: 11 11 2023
entrez: 11 11 2023
Statut: ppublish

Résumé

Left bundle branch area pacing (LBBAP) may be associated with greater improvement in left ventricular ejection fraction and reduction in death or heart failure hospitalization compared with biventricular pacing (BVP) in patients requiring cardiac resynchronization therapy. We sought to compare the occurrence of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) and new-onset atrial fibrillation (AF) in patients undergoing BVP and LBBAP. The I-CLAS study (International Collaborative LBBAP Study) included patients with left ventricular ejection fraction ≤35% who underwent BVP or LBBAP for cardiac resynchronization therapy between January 2018 and June 2022 at 15 centers. We performed propensity score-matched analysis of LBBAP and BVP in a 1:1 ratio. We assessed the incidence of VT/VF and new-onset AF among patients with no history of AF. Time to sustained VT/VF and time to new-onset AF was analyzed using the Cox proportional hazards survival model. Among 1778 patients undergoing cardiac resynchronization therapy (BVP, 981; LBBAP, 797), there were 1414 propensity score-matched patients (propensity score-matched BVP, 707; propensity score-matched LBBAP, 707). The occurrence of VT/VF was significantly lower with LBBAP compared with BVP (4.2% versus 9.3%; hazard ratio, 0.46 [95% CI, 0.29-0.74]; LBBAP was associated with a lower incidence of sustained VT/VF and new-onset AF compared with BVP. This difference remained significant after adjustment for differences in baseline characteristics between patients with BVP and LBBAP. Physiological resynchronization by LBBAP may be associated with lower risk of arrhythmias compared with BVP.

Sections du résumé

BACKGROUND UNASSIGNED
Left bundle branch area pacing (LBBAP) may be associated with greater improvement in left ventricular ejection fraction and reduction in death or heart failure hospitalization compared with biventricular pacing (BVP) in patients requiring cardiac resynchronization therapy. We sought to compare the occurrence of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) and new-onset atrial fibrillation (AF) in patients undergoing BVP and LBBAP.
METHODS UNASSIGNED
The I-CLAS study (International Collaborative LBBAP Study) included patients with left ventricular ejection fraction ≤35% who underwent BVP or LBBAP for cardiac resynchronization therapy between January 2018 and June 2022 at 15 centers. We performed propensity score-matched analysis of LBBAP and BVP in a 1:1 ratio. We assessed the incidence of VT/VF and new-onset AF among patients with no history of AF. Time to sustained VT/VF and time to new-onset AF was analyzed using the Cox proportional hazards survival model.
RESULTS UNASSIGNED
Among 1778 patients undergoing cardiac resynchronization therapy (BVP, 981; LBBAP, 797), there were 1414 propensity score-matched patients (propensity score-matched BVP, 707; propensity score-matched LBBAP, 707). The occurrence of VT/VF was significantly lower with LBBAP compared with BVP (4.2% versus 9.3%; hazard ratio, 0.46 [95% CI, 0.29-0.74];
CONCLUSIONS UNASSIGNED
LBBAP was associated with a lower incidence of sustained VT/VF and new-onset AF compared with BVP. This difference remained significant after adjustment for differences in baseline characteristics between patients with BVP and LBBAP. Physiological resynchronization by LBBAP may be associated with lower risk of arrhythmias compared with BVP.

Identifiants

pubmed: 37950738
doi: 10.1161/CIRCULATIONAHA.123.067465
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

379-390

Auteurs

Bengt Herweg (B)

University of South Florida Morsani College of Medicine, Tampa (B.H., R.B., M.M.).

Parikshit S Sharma (PS)

Rush University Medical Center, Chicago, IL (P.S.S., C.D., S.C.V.).

Óscar Cano (Ó)

Hospital Universitari i Politècnic La Fe and Centro de Investigaciones Biomédicas en RED en Enfermedades Cardiovasculares, Valencia, Spain (O.C.).

Shunmuga Sundaram Ponnusamy (SS)

Velammal Medical College Hospital and Research Institute, Madurai, India (S.S.P.).

Francesco Zanon (F)

Santa Maria Della Misericordia Hospital, Rovigo, Italy (F.Z., L.M.).

Marek Jastrzebski (M)

First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University, Medical College, Krakow, Poland (M.J., P.M.).

Jiangang Zou (J)

The First Affiliated Hospital of Nanjing Medical University, Cardiology, Jiangsu, China (J.Z.).

Mihail G Chelu (MG)

The First Affiliated Hospital of Nanjing Medical University, Cardiology, Jiangsu, China (J.Z.).

Kevin Vernooy (K)

Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, Netherlands (K.V., A.v.S.).

Zachary I Whinnett (ZI)

National Heart and Lung Institute, Imperial College London, United Kingdom (Z.I.W., A.M.L.).

Girish M Nair (GM)

University of Ottawa Heart Institute, ON, Canada (G.M.N., M.G.).

Manuel Molina-Lerma (M)

Hospital Universitario Virgen de las Nieves, Granada, Spain (M.M.-L.).

Karol Curila (K)

Cardiocenter, Third Faculty of Medicine, Charles University, Prague, Czech Republic (K.C.).

Dipen Zalavadia (D)

The Wright Center, Scranton, PA (D.Z.).

Cicely Dye (C)

Rush University Medical Center, Chicago, IL (P.S.S., C.D., S.C.V.).

Sharath C Vipparthy (SC)

Rush University Medical Center, Chicago, IL (P.S.S., C.D., S.C.V.).

Ryan Brunetti (R)

University of South Florida Morsani College of Medicine, Tampa (B.H., R.B., M.M.).

Mishal Mumtaz (M)

University of South Florida Morsani College of Medicine, Tampa (B.H., R.B., M.M.).

Pawel Moskal (P)

First Department of Cardiology, Interventional Electrocardiology and Hypertension, Jagiellonian University, Medical College, Krakow, Poland (M.J., P.M.).

Andrew M Leong (AM)

National Heart and Lung Institute, Imperial College London, United Kingdom (Z.I.W., A.M.L.).

Antonius van Stipdonk (A)

Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, Netherlands (K.V., A.v.S.).

Jerin George (J)

Baylor College of Medicine and Texas Heart Institute, Houston (M.G.C., J.G., Y.K.Q.).

Yusuf K Qadeer (YK)

Baylor College of Medicine and Texas Heart Institute, Houston (M.G.C., J.G., Y.K.Q.).

Jeffrey Kolominsky (J)

Virginia Commonwealth University Medical Center, Richmond (J.K., K.A.E.).

Mehrdad Golian (M)

University of Ottawa Heart Institute, ON, Canada (G.M.N., M.G.).

Ramez Morcos (R)

Geisinger Heart Institute, Wilkes Barre, PA (R.M., F.A.S., P.V.).

Lina Marcantoni (L)

Santa Maria Della Misericordia Hospital, Rovigo, Italy (F.Z., L.M.).

Faiz A Subzposh (FA)

Geisinger Heart Institute, Wilkes Barre, PA (R.M., F.A.S., P.V.).

Kenneth A Ellenbogen (KA)

Virginia Commonwealth University Medical Center, Richmond (J.K., K.A.E.).

Pugazhendhi Vijayaraman (P)

Geisinger Heart Institute, Wilkes Barre, PA (R.M., F.A.S., P.V.).

Classifications MeSH